Based on Tuesday’s evaluation of an abortion pill case, the Supreme Court seems likely to reject a push to curb the distribution of the drug mifepristone. If the court makes its final decision in accordance with the recent discussion, the nation will take a step, however small, in the right direction for preserving reproductive rights. The AHM, however, takes a dangerous stance — one that challenges the authority of the FDA, the third article of the Constitution and the responsibilities of healthcare professionals.
